Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →A grade PMID 42248607
View analysis →A grade PMID 41667193
View analysis →A grade PMID 42260111
View analysis →In a multicentre, single-arm phase 1/2 trial of 55 medically fit adults with relapsed or refractory acute myeloid leukaemia, venetoclax plus cytarabine and mitoxantrone produced a 75% composite complete remission rate, with febrile neutropenia and serious infections prominent and four potentially treatment-related deaths reported.
The trial provides clinical evidence that adding venetoclax to intensive cytarabine–mitoxantrone salvage therapy has activity in fit adults with relapsed or refractory AML; it is reasonable but still inferential to hypothesize that this regimen could improve remission induction and enable more patients to proceed to allogeneic HCT, because efficacy was not compared with a control group and pediatric applicability was not tested.
In a prospective phase II study of 68 patients with resectable head and neck squamous cell carcinoma receiving perioperative pembrolizumab, a genome-wide cfDNA end-motif entropy metric distinguished immunotherapy responders from nonresponders and was associated with disease-free survival.
The study provides evidence that longitudinal regional cfDNA motif diversity correlates with pembrolizumab response; it supports, but does not establish, the hypothesis that rMDS could enable minimally invasive response monitoring or risk stratification after prospective external validation.
In a 39-patient, open-label, single-arm phase 2 study of high-risk neuroblastoma, racotumomab induced anti-mouse and NeuGc-directed immune responses, including ADCC in a minority of patients, with no serious treatment-related adverse events and an exploratory association between IgM response and progression-free survival.
The study provides evidence that racotumomab can elicit NeuGc glycoconjugate-directed antibodies and occasional ADCC in children with high-risk neuroblastoma; it supports, but does not establish, the hypothesis that vaccine-induced immunity against tumor-associated NeuGcGM3 could help control residual disease, particularly in immunologic responders.
In a randomized 35-patient trial of children with newly diagnosed high-risk neuroblastoma and non-progressive disease after intensive initial therapy, dinutuximab alternating with G-CSF/teceleukin produced survival estimates interpreted as comparable to the ANBL0032-based GM-CSF/aldesleukin/isotretinoin regimen, without an obvious difference in frequently recorded grade 3/4 toxicities.
The trial provides preliminary clinical evidence that G-CSF/teceleukin may serve as an alternative cytokine regimen with dinutuximab where GM-CSF, aldesleukin, and isotretinoin are unavailable; equivalence or noninferiority remains an inference requiring confirmation in a larger phase III trial.
In a 650-patient randomized phase III trial of previously untreated, low-risk DLBCL in patients aged 18-80 years, PET-guided reduction to four R-CHOP cycles for early PET-negative patients was noninferior to six cycles and was associated with fewer grade ≥3 and serious adverse events.
The trial directly supports, in the studied adult and young-adult low-risk DLBCL population, the hypothesis that PET negativity after two R-CHOP cycles can identify patients who may receive four rather than six cycles without compromising 3-year progression-free survival while reducing toxicity; application to children or broader-risk DLBCL populations remains an inference not tested by this record.
This phase 1/2 TACL study of 24 pediatric patients with relapsed/refractory ALL found that ixazomib could be combined with relapse chemotherapy at an RP2D of 2 mg/m², with reported acceptable safety, a 67% complete response rate among evaluable patients, and flow MRD negativity in 9 of 14 responders.
The study provides early clinical evidence that adding the oral proteasome inhibitor ixazomib to established relapse chemotherapy is feasible and may have antileukemic activity in pediatric relapsed/refractory ALL; whether ixazomib improves response durability or survival beyond chemotherapy alone remains an untested inference requiring controlled trials.
In this global phase 3 trial of 899 randomized adults with previously untreated high-risk DLBCL or HGBL, adding tafasitamab and lenalidomide to R-CHOP improved progression-free survival but increased grade 3 or higher and fatal treatment-emergent adverse events, while overall-survival results remained immature.
The trial provides evidence that adding anti-CD19 tafasitamab and lenalidomide to first-line R-CHOP can reduce the risk of progression or death in high-risk adult DLBCL or HGBL; it remains an inference that this benefit will translate into longer overall survival or a favorable net clinical benefit, and the supplied record does not establish efficacy or safety in pediatric patients.
In a temozolomide-resistant Th-MYCN neuroblastoma mouse model and derived allografts, molecular profiling identified CDK2-pathway deregulation, and fadraciclib treatment produced significant tumor responses and an overall-survival benefit.
The supplied preclinical evidence supports activity of the CDK2/9 inhibitor fadraciclib in temozolomide-resistant neuroblastoma; it is reasonable, but not yet clinically demonstrated, to hypothesize that CDK2/9 inhibition could overcome or exploit resistance-associated dependencies in relapsed neuroblastoma and improve responses to temozolomide-based therapy.
This review summarizes genomic targets and emerging therapies in T-ALL, including pediatric/AYA front-line benefit reported with nelarabine, an approximately 80% response rate for daratumumab plus chemotherapy, and response rates above 90% in early-phase CAR-T trials for relapsed/refractory disease.
The supplied record reports encouraging clinical activity for nelarabine, daratumumab-based therapy, and early CAR-T approaches; it supports the inference that genomically informed targeting and immunotherapy could improve front-line or salvage outcomes in T-ALL, but comparative benefit, durability, safety, and appropriate patient selection remain unestablished for most emerging approaches.
This single-center phase 1 trial reports that repeated intracerebroventricular B7-H3 CAR T-cell infusions were feasible and tolerable in children and young adults with diverse recurrent/refractory CNS tumors or non-pontine diffuse midline glioma, with two partial responses among 26 treated patients.
The trial provides human evidence that repeated locoregional delivery of B7-H3 CAR T cells is feasible and tolerable; it supports, but does not establish, the hypothesis that targeting B7-H3 within the CNS could produce clinically meaningful antitumor activity in selected pediatric CNS tumors.
This phase II trial enrolled 60 patients with high-risk neuroblastoma in second or later complete remission and reported 2- and 5-year progression-free survival rates of 55% and 50% after five cycles of naxitamab plus stepped-up GM-CSF, while acknowledging potential confounding from subsequent investigational therapies.
The trial provides clinical evidence that naxitamab plus stepped-up GM-CSF can be administered as post-relapse remission consolidation with encouraging long-term progression-free survival; it remains an inference, rather than a controlled conclusion, that this regimen itself prolongs remission because no comparator is reported and many patients received post-protocol vaccine therapy.
This narrative review synthesizes mechanisms of anthracycline cardiotoxicity and evidence for pharmacologic cardioprotection, identifying dexrazoxane as the only approved preventive agent with adult and pediatric support while describing several less-established strategies.
The reviewed evidence supports dexrazoxane and suggests modest cardiac-function preservation with selected neurohormonal agents and statins; it is plausible, but not established by this review, that early risk-guided use of these or emerging metabolic therapies could reduce anthracycline-related cardiac injury in pediatric oncology patients.
